China’s life sciences sector is undergoing rapid transformation, driven by advancements in genomic innovation, particularly in next-generation sequencing (NGS). The NGS market is projected to grow at a compound annual rate of about 9% from 2026 to 2036, spurred by increasing investment in precision medicine and expanding clinical applications. Notably, China accounted for nearly 32% of the Asia-Pacific NGS market in 2025.
Key players like MGI Tech are enhancing their capabilities through recent acquisitions, including STOmics and CycloneSEQ, which focus on spatial biology and nanopore sequencing, respectively. These technologies enable advanced studies in cancer, developmental biology, and neuroscience by providing detailed spatial mapping and long-read sequencing features.
Overall, China’s ambitions in genomics technology, backed by government support and a growing healthcare infrastructure, position it as a potential global leader in this field. As sequencing costs fall and applications expand, the Chinese NGS market is set to be one of the fastest-growing segments globally.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://oncodaily.com/health-policy/genomic-innovation
